---
title: "Incannex Receives A$6.0M R&D Tax Refund, Expects A$11.1M+ in Non-Dilutive Funding"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289319892.md"
description: "Incannex Healthcare received A$6.04 million in R&D tax incentive proceeds, boosting its cash position. The company expects over A$11.1 million in total non-dilutive funding by late 2026. These funds strengthen the balance sheet without dilution or debt, supporting clinical programs like IHL-42X and PSX-001, as well as a share repurchase program."
datetime: "2026-06-10T11:33:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289319892.md)
  - [en](https://longbridge.com/en/news/289319892.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289319892.md)
---

# Incannex Receives A$6.0M R&D Tax Refund, Expects A$11.1M+ in Non-Dilutive Funding

**Incannex received A$6.04 million in R&D tax incentive proceeds and expects more than A$11.1 million in non-dilutive funding in 2026.**

**Key Highlights:**

-   Received A$6,039,162.43 under Australia’s R&D Tax Incentive Program, boosting cash position.
-   expects an additional ~A$5.1 million in R&D proceeds later in 2026, bringing total to \>A$11.1M.
-   Proceeds are non-dilutive, strengthening balance sheet without issuing shares or taking on debt.
-   Funds provide flexibility to advance clinical programs including IHL-42X and PSX-001.
-   Also supports shareholder-focused capital allocation, including active share repurchase program.

Original SEC Filing: Incannex Healthcare Inc. \[ IXHL \] - 8-K - Jun. 10, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [IXHL.US](https://longbridge.com/en/quote/IXHL.US.md)

## Related News & Research

- [Incannex starts screening patients in Phase 2 DReAMzz trial of IHL-42X for sleep apnea](https://longbridge.com/en/news/293607970.md)
- [AWI: Double-digit sales and earnings growth in Q2 2026 led to raised full-year guidance](https://longbridge.com/en/news/294046869.md)
- [Teradata (TDC) Faces A Fresh AI Test Following Its Platform Launch](https://longbridge.com/en/news/293850716.md)
- [Forrester sets agenda for 2026 Security & Risk Forum](https://longbridge.com/en/news/293936643.md)
- [FactSet Research Systems (FDS) Could Be 10% Below Fair Value On RepRisk Partnership](https://longbridge.com/en/news/294318958.md)